AGT and COVID-19: There are some pathophysiological changes secondary to COVID-19 infection that may contribute to a greater chance of patients infected with COVID-19 to develop thrombotic complications as an increased angiotensin II expression secondary to angiotensin-converting enzyme 2 receptor binding and consequently augmented plasminogen activator inhibitor C-1 expression with a reduced fibrinolysis in the anticoagulation system [39].